Information Center

  • Move News
  • Move FAQ
  • inquiry

News News

Total 76

News Search
  • Samyang Holdings Biopharmaceuticals Division 2022.04.07
    Samyang Holdings Exhibits ‘Croquis’ in AMWC 2022
    Samyang Holdings Exhibits ‘Croquis’ in AMWC 2022

    - Shared test and research results on its new facelift thread brand Croquis - Set up an exhibition booth and discussed expansion of partnership with global companies - “Will accelerate the expansion to the global market in response to the growing demand in the cosmetic surgery market upon the brand reopening”   ▲ Samyang Holdings Biopharmaceuticals Division participated in the Aesthetic and Anti-aging Medicine World Congress (AMWC) 2022, and promoted the excellence of its facelift thread brand Croquis.   The facelift thread brand Croquis from Samyang Holdings Biopharmaceuticals Division is accelerating its global marketing campaign targeting the brand reopening. The name croquis originates from a drawing technique that quickly sketches the outlines of a model and fittingly, the product promotes its ability to lift up the facial outlines quickly and naturally.   Samyang Holdings Biopharmaceuticals Division (President Lee Young-Joon) announced on April 6 that the company participated in the Aesthetic and Anti-aging Medicine World Congress (AMWC) 2022 held in Monaco from March 31 to April 2 local time to showcase the excellence of its facelift thread brand Croquis.   This year marks the 20th anniversary of AMWC, one of the two biggest aesthetic and anti-aging conferences in the world. It drew 10,000 aesthetic and cosmetic surgery specialists from 120 countries. Last year’s conference was organized in a hybrid format where in-person events were streamed live due to the COVID-19 pandemic. This year, the conference was organized around in-person events as intended.   The Biopharmaceuticals Division shared its test and research findings with South Korean and worldwide medical professionals, and set up an exhibition booth promoting Croquis’ quality and efficacy. In particular, on the first day of the congress on the 31st, Drs. Hema Sundaram and Henry Delmar, medical practitioners from the US and France, respectively, gave a presentation on the outcomes of international Croquis clinical trials, which drew a lot of attention.   A Croquis official said, “We participated in the conference in order to promote surgery techniques using Croquis and the clinical cases to medical professionals around the world, and to provide consultation services to global companies in order to increase the export volume and region. We will accelerate the expansion to the global market in response to the increasing demand in aesthetic and cosmetic surgery upon the endemic and resumption of economic activities.”   Croquis, a facelift thread brand from Samyang Holdings Biopharmaceuticals Division, targeted the global market right from the launch, releasing global case studies and research results while proving its efficacy and safety to the world through data. The company has signed sales contracts in 17 countries, including Japan and European countries, and is also seeking marketing approval in Brazil and Australia.   Meanwhile, the Biopharmaceuticals Division gained trust from the global cosmetic surgery industry by reasonable, data-based marketing, earning its second-mover advantage. While the conventional aesthetic facelift thread brands emphasize the change before and after the procedure, the Biopharmaceuticals Division is currently conducting research with key opinion leaders to secure clinical evidence to ensure safe and effective facelift procedures.  

  • Samyang Holdings Biopharmaceuticals Division 2021.11.19
    Samyang Holdings Biopharmaceuticals Division’s Signs Export Agreement for “Croquis” To UK, Accelerating Expansion Into Europe
    Samyang Holdings Biopharmaceuticals Division’s Signs Export Agreement for “Croquis” To UK, Accelerating Expansion Into Europe

    - Exclusive supply agreement signed with UK cosmetic surgery product distributor Church Pharmacy - Strategic direction aligned with Samyang’s pursuit of digital marketing, which is expected to generate synergy - Aims to expand sales across Europe by 2025, starting with the UK   ▲ Product packaging of Croquis, a facelift thread brand of Samyang Holdings Biopharmaceuticals Division. Samyang Holdings (CEO: Eum Tae-woong) Biopharmaceuticals Division signed an exclusive supply agreement with Church Pharmacy (United Kingdom).   Croquis, a facelift thread brand of Samyang Holdings Biopharmaceuticals Division, is accelerating expansion into global markets. The brand’s name was inspired by “croquis,” a rough sketch technique used to quickly bring out subjects’ features, conveying the meaning that facial outline is lifted quickly and naturally.   Samyang Holdings (CEO: Eum Tae-woong) Biopharmaceuticals Division announced on Nov. 17 that it had signed an exclusive supply agreement with the UK medical aesthetic (cosmetic surgery) product distributor Church Pharmacy.   Church Pharmacy, headquartered in Loughborough, United Kingdom, is playing a leading role in the European cosmetic surgery market by establishing a distribution network in the UK and EU based on cosmetics and plastic surgery-related portfolios, including botulinum toxin, filler, cosmeceutical (cosmetics + pharmaceutical). In addition, Church Pharmacy has been playing a role as an opinion leader in the cosmetics surgery field by promoting products of Church Pharmacy through demonstration to UK’s doctors and patients and sharing clinical cases, based on a close cooperative relationship it had built with key doctors (competent doctors delivering new medical products and techniques to doctors).   An official from Samyang Holdings Biopharmaceuticals Division said, “Church Pharmacy has gained high trust from customers by actively carrying out the academic marketing strategy based on its solid distribution network. We signed the agreement in the beliefs that synergy effect can be created thanks to the alignment of our strategic directions as Samyang Holdings Biopharmaceuticals Division also pursue data-oriented marketing.”   Starting with this agreement, Samyang Holdings Biopharmaceuticals Division’s plans to accelerate its expansion into European markets by 2023, establishing and strengthening the sales base of five European countries, including the UK, France, Germany, Spain and Italy, and continue to expand sales across Europe by 2025.   Meanwhile, Samyang Holdings Biopharmaceuticals Division has conducted a data-oriented marketing strategy, thereby overcoming the disadvantages as a latecomer, gaining trust in the global cosmetics surgery industry. In contrast with other established companies providing cosmetic surgery threads, which put emphasis only on the comparison between before-and after-medical procedures, Samyang Holdings Biopharmaceuticals Division is building up various data to prove the correlation between the effects of medical procedures by facial area and physical properties of thread, in pursuit of evidence-based marketing.    

  • Samyang Holdings Biopharmaceuticals Division 2021.10.08
    Samyang Holdings Biopharmaceuticals Division shares biliary tract cancer treatment case using “Genexol PM” at a global webinar
    Samyang Holdings Biopharmaceuticals Division shares biliary tract cancer treatment case using “Genexol PM” at a global webinar.

    - Shared the effects and safety of Genexol PM with medical specialists in biliary tract cancer in Southeast Asia - Researcher-initiated clinical trial in progress for Genexol PM application to biliary tract cancer treatment with completion targeted for 2024 - Improved the shortcoming of paclitaxel of not dissolving well in water using drug delivery systems to enable high dosage administration       ▲ Samyang Holdings Biopharmaceuticals Division holds a global webinar on “biliary tract cancer treatment using Genexol PM.”   Samyang Holdings Biopharmaceuticals Division embarks on biliary tract cancer treatment with Genexol PM, an anticancer drug.   Samyang Holdings Biopharmaceuticals Division (CEO: Eom Tae-woong) announced on October 6 that the company had hosted a global webinar on “biliary tract cancer treatment using "Genexol PM (export name for Southeast Asia: Paxus PM)” and shared the latest trends of biliary tract cancer treatment using Genexol PM with medical specialists in anticancer treatment in Southeast Asia. Genexol PM is an anticancer drug that has improved on the shortcoming of Genexol Inj. (active ingredient: paclitaxel) for breast cancer, ovarian cancer, and lung cancer.   This webinar was held as a small-scale lecture where only 35 medical specialists in biliary tract cancer treatment from Thailand, Malaysia, Myanmar, and the Philippines were invited. It was led by Dr. Chong Kwang Jeat from Mahkota Medical Centre in Malaysia, and Professor Dr. Kim Kyu-pyo, an oncologist at Asan Medical Center in Seoul, gave the lecture.   Dr. Kim presented the biliary tract cancer prevalence rates in Korea and Southeast Asian countries and introduced the latest trends and expertise in biliary tract cancer treatment. In particular, Dr. Kim drew the attention of global medical personnel attending the webinar by sharing the effects and safety of Genexol PM for biliary tract cancer treatment.   Since 2013, Samyang Holdings Biopharmaceuticals Division—in cooperation with Seoul National University Hospital among others—has been continuously conducting a study to verify the effects and safety of Genexol PM for biliary tract cancer treatment and presenting the study paper at domestic and international conferences. Currently, the Biopharmaceuticals Division is jointly conducting a large-scale researcher-initiated clinical trial with Asan Medical Center in Seoul—which it aims to complete by 2024—in order to verify additionally the treatment effects and safety of Genexol PM and to promote the drug administration. Biliary tract cancer patients are experiencing difficulties in receiving treatment as the number of drugs available for administration is smaller than that of other cancers and the administration methods are not diverse.   Genexol PM was released in 2006 as an incrementally modified drug of Genexol to improve on the shortcoming of paclitaxel, which is not easily dissolved in water, using the Biopharmaceuticals Division’s drug delivery system (DDS). While traditional paclitaxel injections have had a limitation in dose due to toxicity/side effects associated with solubilizer, Genexol PM, however, enables high-dose administration as the solubilizer is replaced with DDS.   “The biliary tract cancer prevalence rates in Korea and Southeast Asian countries are relatively higher. Through the investigator-initiated clinical trial for the Genexol PM application to biliary tract cancer treatment, which is being conducted at the moment, we will promote drug administration. We are expecting this will help patients suffering from biliary tract cancer across the world,” an official from Samyang Holdings Biopharmaceuticals Division said.   Samyang Holdings succeeded in the mass production of paclitaxel from plant cell culture for the first time in the world in 1995. After it started exporting drug substances in 2002, the company also began to export Genexol Inj. drug products in 2003. Currently, Samyang Holdings is exporting various anticancer drug substances and products to 50 companies in about 20 countries around the world including advanced ones such as Germany and Japan.   In partnership with "Kalbe International," Samyang Holdings exports Genexol PM under the name of Paxus PM to Indonesia, Vietnam, the Philippines, Malaysia, and Thailand. The company also started the export to Myanmar last month. Kalbe International is a subsidiary responsible for exporting and importing pharmaceuticals under the Kalbe Group, the largest pharmaceutical group in Indonesia.

  • Samyang Holdings Biopharmaceuticals Division 2021.09.03
    Samyang Biopharm USA and Spanish National Research Council to Conduct Joint Research on Mechanism of New Drug Candidates
    Samyang Biopharm USA and Spanish National Research Council to Conduct Joint Research on Mechanism of New Drug Candidates

      - Joint research on the mechanism of NK cell activation of SYB-010, an immunotherapy drug candidate - Activation of NK cells activation by binding MIC-A/B and exosomes containing MIC-A/B - Confirmation of immuno-oncology effects through animal experiments, such as increased survival rate, and reduction of tumor growth and metastasis   ▲ Samyang Biopharm USA logo   Samyang Biopharm USA continues to pursue open innovation to develop new immunotherapy drugs.   Samyang Biopharm USA (CEO: Hyun-Jung Helen Lee) announced on September 1 that it has concluded a joint research contract with the Spanish National Research Council (CSIC) to investigate the mechanism of action of SYB-010, an immunotherapy drug candidate under study. CSIC is the largest public research institute in Spain.   Through this joint research, Samyang Biopharm USA and CSIC is scheduled to confirm the mechanism by which SYB-010 treats cancer by activating NK cells. The research team found that SYB-010 not only activates NK cells, but also binds to MIC (MHC class I polypeptide-related sequence) A and B isolated from the surface of cancer cells. It is also expected to bind with MIC-A/B contained in exosomes that are released by cancer cells (nano-unit small cells that plays the role of intercellular signal communication).   MIC-A/B on the surface of cancer cells act as indicators for NK cells, cells of our innate immune system, to recognize cancer. When NK cells recognize MIC-A/B and exosomes separated from cancer cells as cancer and attacks them, the immune action against cancer cells is weakened. When SYB-010 blocks these interfering substances, NK cells recognize the cancer more accurately and attacks the cancer. NK cells are immune cells that destroy abnormal cells, such as virus-infected cells or cancer cells.   CEO Hyun-Jung Helen Lee of Samyang Biopharm USA stated that “SYB-010 has great potential to be developed as a new immunotherapy drug,” and affirmed that “the research collaboration with CSIC, who has extensive clinical trial experience, will be a great opportunity to validate the potential of SYB-010.”   Drs. Valés-Gómez and Reyburn of CSIC Immunology and Oncology Research Group agreed that “this is an important study that will help improve our overall understanding of cell receptors and the ligands that bind to them,” and was optimistic that “through this joint research, we hope that SYB-010 can be developed as a new immunotherapy drug.”   Dr. Sean McKenna, principal investigator of Samyang Biopharm USA stated that “CSIC has various experiences in analyzing the immunomodulatory effects of antibodies based on its specialized scientific technology,” and added that “through this joint research, we will develop an effective and safe immunotherapy drug by clearly identifying the anticancer mechanism of SYB-010.”   SYB-010 is a monoclonal antibody artificially made to bind to a specific protein. As a result of administering SYB-010 in an animal tumor model, SYB-010 was successful in binding to the MIC (sMIC) separated from cancer cells to activate the NK cells and significantly reduce tumor growth. The animal tumor model showed a clear anticancer immune effect, such as reducing the metastasis of cancer and increasing the survival rate. Samyang Biopharm USA was introduced to SYB-010 by CanCure of the United States in 2019 and secured exclusive rights to the global development, manufacture and commercialization of this substance. Currently, study is being conducted with the goal of obtaining IND approval by the US Food and Drug Administration (FDA) in 2022.   At present, Samyang Biopharm USA also signed a three-year research cooperation agreement with Dr. Hyun-Sung Lee of Baylor School of Medicine to investigate the association between sMIC expression and sMIC expression in patients who do not show therapeutic effects of immune checkpoint inhibitors. Samyang Biopharm USA, through research with Dr. Lee, was able to confirm the usage method of sMIC to identify patients who do not show therapeutic effect of existing immune checkpoint inhibitors. Thus, Samyang Biopharm USA strives to use SYB-010 to overcome the limitations of immune checkpoint inhibitors where only partial patients respond to treatment.   Samyang Biopharm USA is an overseas corporation of Samyang Holdings established in the center of the global bio industry at Kendall Square, Boston in August 2018 with the goal of developing innovative oncology drugs and rare disease treatments. Samyang Biopharm USA intends to increase the speed and success rate of biopharmaceutical development by conducting global clinical trials of new oncology drug candidates studied by the headquarters in Korea through the implementation of the open innovation strategy, that aims to introduce and develop new biopharmaceutical technologies and materials at an early stage by making the most of the location. Currently, the company continues to search for new drug candidates targeting immunotherapy and rare disease treatments.  

  • Samyang Holdings Biopharmaceuticals Division 2021.08.26
    Samyang Holdings Biopharmaceuticals Division’s “Croquis” Wins 2021 Red Dot Design Award
    Samyang Holdings Biopharmaceuticals Division’s “Croquis” Wins 2021 Red Dot Design Award

    - Winner of the 2021 Red Dot Design Award, one of the world’s top three design awards - Line drawn product packaging with black lines against a white background displaying brand significance and features - Five different yet unified designs for each product type   ▲ Product packaging of Croquis, a facelift thread brand of Samyang Holdings Biopharmaceuticals Division, which was awarded the 2021 Red Dot Design Award (for brands and communication design). The line drawing method visually depicts the brand significance, aimed at quickly and naturally shaping facial contours. Each design displays uniqueness and creativity, yet a unified look.   Samyang Holdings (CEO: Eum Tae-woong) Biopharmaceuticals Division announced on Aug. 23 that Croquis won the 2021 Red Dot Design Award (for brands and communication design). Croquis is a facelift thread brand of Samyang Holdings Biopharmaceuticals Division.   Since 1955, Design Zentrum Nordrhein Westfalen has led the Red Dot Design Award, one of the world’s top three design awards along with iF Product Design Award and the International Design Excellence Awards. In this award ceremony, the best design is selected annually based on its excellence, creativity, and functionality in three divisions: product design, brands and communication design, and design concept. In 2021, 7,800 artworks were exhibited in roughly 60 countries, and 50 design experts conducted a blind evaluation.   The product packaging of Samyang Holdings Biopharmaceuticals Division’s Croquis was inspired by “croquis,” a rough sketch that brings out the object’s characteristics. It earned high points and awarded as winner for an artistic and visual depiction of the brand identity that resonates with consumers and increases customers’ satisfaction.   Croquis product packaging features a sketch of various facial angles using a “line drawing” technique, marking various black lines against a white background. The brand identity was effectively and naturally conveyed through this technique, as the product quickly and naturally and beautifully shapes facial contours. In addition, five different drawing methods were applied for each design, which was unique yet unified. A spokesperson from Samyang Holdings Biopharmaceuticals Division said, “We made sure the design intuitively displayed the brand significance and features of Croquis at a glance. We will continue to develop designs that are easy for consumers to understand and provide differentiated use convenience.”   Meanwhile, Croquis gained trust from the global cosmetic surgery industry by reasonable, data-based marketing, earning its second-mover advantage. Currently, Croquis is sold in roughly 10 countries, including Germany and the UK, and various promotions and academic marketing are being implemented in each nation through webinars to reach cosmetic surgery medical teams worldwide.

  • Samyang Holdings Biopharmaceuticals Division 2021.08.23
    Samyang Holdings Biopharmaceuticals Division Promotes “Croquis” With Global SAB
    Samyang Holdings Biopharmaceuticals Division Promotes “Croquis” With Global SAB

    - Recruitment of a Swedish plastic surgeon to the SAB to give presentations in global cosmetic surgery conferences and conduct advisory activities - Presentation of the efficacy and safety of Croquis at a cosmetic surgery conference in September - Expansion of the overseas business base with data-based academic marketing activities through collaboration with global health professionals       ▲ Dr. Fredrick Berne, a plastic surgeon from Sweden Dr. Berne will officially start working as a member of Samyang Holdings Biopharmaceuticals Division’s SAB starting in September.     Samyang Holdings Biopharmaceuticals Division has added a global health professional to its Scientific Advisory Board (SAB) to promote the safety and efficacy of Croquis worldwide. Croquis is a face-lift thread brand of Samyang Holdings Biopharmaceuticals Division.   Samyang Holdings (CEO: Eom Tae-woong) announced on August 18 that the company recruited Dr. Fredrick Berne, a plastic surgeon from Sweden, to its SAB.   Dr. Berne has worked as a researcher and advisor for global aesthetic companies based on his extensive experience in cosmetic facial procedures and plastic surgery. He also serves as a advisor for major cosmetic surgery societies, including the one of the world’s top three International Master Course on Aging Science (IMCAS). With Dr. Berne on the SAB, Samyang Holdings Biopharmaceuticals Division now has a total of five cosmetic and plastic surgeons—three international and two domestic.   Dr. Berne will begin his official activities as a member of the SAB with a presentation in the Aesthetic and Anti-Aging Medicine World Congress (AMWC) to show clinical cases demonstrating the efficacy and safety of Croquis and suggesting effective procedure techniques. In addition, he will conduct research together to obtain clinical cases from overseas and develop a standard procedure technique which can improve the effect of Croquis, and serve as a speaker in academic webinars, introducing and demonstrating Croquis-based techniques.   An official from Samyang Holdings Biopharmaceuticals Division said, “To target global markets, it is necessary to obtain various cases with different procedures applied to different races for medical devices like face-lift threads as different races have different anatomical features, such as facial and bone structures, and cosmetic effects vary depending on race. Collaboration with health professionals recognized around the world will serve as a good opportunity to demonstrate the efficacy and safety of Croquis.”   Meanwhile, Samyang Holdings Biopharmaceuticals Division will continue to promote Croquis to international plastic surgeons through a variety of contractless academic marketing activities. In the first half of the year, the company participated in the International Seminar & Workshop in Aesthetic Medicine (IMCAS I-SWAM) and shared the latest Croquis-based face-lift procedure online. Samyang Holdings will focus on strengthening academic marketing through webinars with different countries, and promoting a safe and effective procedure for Croquis.   In addition, Croquis overcame disadvantages as a latecomer with data-oriented and evidence-based marketing, and is earning trust in global aesthetic medicine markets. While traditional aesthetic thread brands only compare and emphasize preoperative and postoperative effects, Croquis aims for evidence-based marketing and is making its best effort to obtain various data to prove a correlation between operative effects by parts of the face and the thread’s physical properties together with dermatologists and plastic surgeons in the US, France and Spain.

  • Samyang Holdings Biopharmaceuticals Division 2021.08.17
    SRDDS MOU Between Samyang Holdings Biopharmaceuticals Division and G2GBIO
    SRDDS MOU Between Samyang Holdings Biopharmaceuticals Division and G2GBIO

    - MOU signed for technical and development cooperation of sustained release injectables that lasts more than a month - Drug wrapped with biodegradable polymer for controlled release in the body - Improvement of drug compliance and convenience through combination of biodegradable polymer technology and microsphere technology from both companies   ▲Samyang Holdings Biopharmaceuticals Division and G2GBIO signed an MOU to develop sustained release injectable products at the Samyang Discovery Center in Pangyo on the 9th. From left, Head of PU Lee Yong-jin (Biopharmaceuticals Division), CEO Eom Tae-woong (Samyang Holdings), CEO Lee Heeyong (G2GBIO), and Managing Director Lee Su-jeong (R&D Center).   Samyang Holdings Biopharmaceutical Division is promoting the R&D and commercialization of sustained release injectables through open innovation using drug delivery technology (DDS). DDS is a technology that effectively delivers drugs into the body to reduce side effects and maximize medicinal effects.   Samyang Holdings (CEO: Eom Tae-woong) Biopharmaceuticals Division announced on the 9th that it had signed a memorandum of understanding (MOU) with the sustained release drug delivery system (SRDDS) developer G2GBIO (CEO: Lee Heeyong) to initiate the development of sustained release injectables. SRDDS is a drug with sustained release of medicinal efficacy for up to several weeks to several months. This helps to improve dosing convenience for patients who have difficulty taking regular medications or chronic disease patients who are required to take daily medications.   According to this MOU, Samyang Holdings Biopharmaceuticals Division will develop and supply biodegradable polymers for medical use, in which G2GBIO will use this to initiate research and development of sustained release injectables by producing microspheres. Microspheres are spherical particles of approximately 10 to 100 µm. Through this MOU, the two companies are scheduled to cooperate in all directions, from market research and development strategies for sustained release injectables to development of commercialization technology and discussions on the distribution rights of the finished products.   SRDDS is based on a technology that controls the drug to be slowly released from the body to maintain a constant concentration by wrapping the drug in biodegradable polymer. The key element of this technology is the biodegradable polymer material. This is because the dissolution of microspheres and the rate of drug release varies depending on the type and dissolution of the biodegradable polymer material.   Since 1993, Samyang Holdings Biopharmaceuticals Division has succeeded in developing biodegradable surgical sutures using biodegradable polymers for the first time in Korea. It has accumulated Korea’s best capabilities for biodegradable polymers and is capable of designing optimal polymers tailored to the required drug properties. In addition, stable raw material supply is possible due to the company’s own factory that is capable of producing biodegradable polymer materials and raw materials.   Another key technology in the development of sustained release injectables using the microsphere-based DDS technology is the production of microspheres in uniformed sizes. This is because the dissolution rate and drug release amount may vary depending on the degree of uniformity of the microsphere size. Although production of uniform sized microspheres can be realized to some extent in the research stage, quality assurance is difficult to achieve in mass production. This is why it is difficult for latecomers to enter this market.   G2GBIO’s patented “Innovative Long Acting Micro Particle” (InnoLAMP) technology is capable of producing uniformed sizes of microspheres through their self-developed microsphere manufacturing technology. In addition, a GMP plant for clinical product production equipped with aseptic facilities is available, in which production facilities more than ten times the size are being prepared. There are only about ten companies worldwide capable of commercial production of sustained release microspheres. Based on the mentioned technology, G2GBIO is focused on research and development for dementia treatment and diabetes treatment with sustained medicinal effect for up to a month, and post-operative pain treatment with sustained medicinal effect for up to a week. CEO Eom stated “Samyang Holdings Biopharmaceuticals Division has a diverse portfolio of biodegradable polymer materials and its own production plant, including polymer synthesis technology, so it is possible to supply substances tailored to the properties of drugs.” He added, “We will strive to improve the convenience of drug administration for patients by developing SRDDS that combines the technologies and infrastructures of both companies beyond simple substance supply.”   CEO Lee stated “Samyang Holdings Biopharmaceuticals Division has excellent technology and is the first in Korea to develop biodegradable surgical sutures.” He added, “Since the role of biodegradable polymers is important for sustained release drugs, we expect that this agreement will enhance product competitiveness and make it easier to enter overseas markets.”   Samyang Holdings Biopharmaceuticals Division has invested heavily in DDS from the beginning of its entry into the pharmaceutical business. In the late 1990s, it launched improved new drugs, such as Genexol® PM Inj. and Nanoxel® M Inj. using DDS technology as well as a DDS through the skin, such as the smoking cessation aid Nicostop® Patch and arthritis treatment Rheumastop® Plaster. Samyang Holdings Biopharmaceuticals Division has developed its own differentiated DDS platform that can be applied to biopharmaceuticals, among others, while also promoting the development of new drugs using the platform. Recently, it signed an MOU with mCureX, a subsidiary of the gene therapy developer OliX Pharmaceuticals, to develop a COVID-19 vaccine, and is researching an mRNA vaccine using stability enhanced nanoshell (mSENS), an independent DDS technology of Samyang Holdings Biopharmaceuticals Division.   Founded in 2017, G2GBIO is a biotech company specializing in the development of long-acting medicines. Currently, an investigational new drug (IND) is in progress for the development of a global improved drug for the treatment of sustained release dementia, and plans to continuously promote technology transfer and joint development in the future. Since its establishment, G2GBIO has secured approximately KRW 21.4 billion in investment attraction so far. Investors include Korea Investment Partners which participated in both Series A and B, QUAD Investment Management, Seoul Investment Partners, Emford Equity Partners, BNK Venture Capital, Industrial Bank of Korea, Arc Impact Asset Management, KDB Bank, CKD Venture Capital, Daedeok Venture Partners, AG Investment, G2G Invest Partners, and Biotoxtech.

  • Samyang Holdings Biopharmaceuticals Division 2021.04.05
    Samyang Biopharmaceuticals Corporation’s Bendalid Inj. Signaling Successful Market Entry
    Samyang Biopharmaceuticals Corporation’s Bendalid Inj. Signaling Successful Market Entry

      - Seeks to enter large hospitals in just 1 month since its launch, and is under review by the DC in 15 hospitals - Ensures safety without injecting nitrogen gas with its independently developed method using drug substances from Germany - Seeks to expand abroad as the only generic launched in both 25 mg and 100 mg bottles   ▲Blood cancer drug Bendalid Inj. successfully localized by Samyang Biopharmaceuticals Corporation   Samyang Biopharmaceuticals Corporation’s blood cancer drug Bendalid Inj. (ingredient: bendamustine) is signaling successful market entry as it seeks to advance into large hospitals in just 1 month since its launch.   Samyang Biopharmaceuticals Corporation (CEO Eom Tae-ung) announced on Mar. 31 that Bendalid Inj. is under review by the drug committee (DC) of 15 university hospitals. The DC procedure intends to determine whether a drug can be prescribed in a hospital.   Bendalid Inj. is a generic drug of Eisai Korea’s Symbenda Inj. and has indications for combination therapy with the target anti-cancer drug rituximab in follicular lymphoma, a malignant tumor in lymphatic tissue, chronic lymphocytic leukemia, a type of blood cancer, and multiple myeloma.   Samyang Biopharmaceuticals Corporation has successfully localized bendamustine, for which the country has solely relied on imports, and launched the first generic in both 25 mg and 100 mg bottles on Mar. 1. Except for the original drug’s company, Samyang Biopharmaceuticals Corporation is the only company that launches bendamustine in both doses of 25 mg and 100 mg.   In particular, Samyang Biopharmaceuticals Corporation’s Bendalid Inj. ensures safety without injecting nitrogen gas with its independently developed low-temperature manufacturing method and uses drug substances from Germany to improve reliability in quality.   An official from Samyang Biopharmaceuticals Corporation said, “Samyang Biopharmaceuticals Corporation is the only company in Korea that can produce both 25 mg and 100 mg bottles of bendamustine. As Pharmaceutical Plant in Daejeon, which produces Bendalid Inj., has been certified for European and Japanese GMP, we will expand abroad.”   Meanwhile, Samyang Biopharmaceuticals Corporation began to expand its cytotoxic anti-cancer injection factory last year to boost its global contract development and manufacturing organization (CDMO) business. Currently, a factory whose expected total capacity covers 5 million vials including 4 million liquid injection vials and 1 million lyophilisation vials is being expanded in Daejeon.

  • Samyang Holdings Biopharmaceuticals Division 2021.03.22
    Samyang Biopharmaceuticals Corporation Hosted Webinar for Oncologists in Southeast Asia
    Samyang Biopharmaceuticals Corporation Hosted Webinar for Oncologists in Southeast Asia

    - Shared the latest trends in anticancer therapy using “Genexol PM” with 200 healthcare professionals from Korea, Vietnam, Malaysia, and Thailand - Exporting drug substances and drug products to 50 companies in 20 countries including advanced ones such as Germany and Japan - “We will continue to host online webinars to share the latest insights on Genexol PM and various anticancer drugs” ▲ Around 200 healthcare professionals attended a webinar hosted by Samyang Biopharmaceuticals Corporation.   Samyang Biopharmaceuticals Corporation shared the latest trends in anticancer therapy based on Genexol PM Inj. with oncologists in Southeast Asia. Genexol PM is an anticancer drug that has improved the shortcoming of Genexol Inj. (active ingredient: paclitaxel) for breast cancer, ovarian cancer, and lung cancer.   Samyang Biopharmaceuticals Corporation (CEO: President Eom Tae-ung) announced on March 15 that the company hosted a webinar under the title of “Breast Cancer Patient Treatment with Genexol PM (export name for Southeast Asia: Paxus PM)” participated by around 200 healthcare professionals from Korea, Vietnam, the Philippines, Malaysia, and Thailand.   In this webinar, Prof. Kim Sung-bae from the Department of Oncology, Asan Medical Center and Dr. Mohamed Ibrahim A. Wahid from Beacon Hospital, Malaysia, gave presentations. Professor Kim, who participated in a Phase III trial of breast cancer, shared the effect and latest clinical cases of Genexol PM Inj. in breast cancer patients.   Genexol PM Inj., to which Samyang Biopharmaceuticals Corporation’s drug delivery system was applied to overcome the shortcoming of paclitaxel which hardly dissolves in water, was launched in 2006 in Korea. While traditional paclitaxel injections have had a limitation in dose due to toxicity/side effects associated with solubilizer, Genexol PM do not include any solubilizer, thus enabling the high-dose administration.   Southeast Asian healthcare professionals attending the webinar asked breast cancer treatment experiences using Genexol PM and showed great interest in Genexol PM.   Samyang Biopharmaceuticals Corporation succeeded in mass production of paclitaxel from plant cell culture for the first time in the world in 1995. After it started exporting drug substances in 2002, the company also began to export Genexol Inj. drug products since 2003. Currently, Samyang Biopharmaceuticals Corporation is exporting various anticancer drug substances and products to 50 companies in about 20 countries around the world including advanced ones such as Germany and Japan.    In partnership with “Kalbe International,” Samyang Biopharmaceuticals Corporation exports Genexol and Genexol PM under the name of Paxus and Paxus PM to Indonesia, Vietnam, the Philippines, Malaysia, and Thailand. The company will soon export them to Myanmar as well. Kalbe International is a subsidiary responsible for exporting and importing pharmaceuticals under the Kalbe Group, the largest pharmaceutical group in Indonesia.   An official from Samyang Biopharmaceuticals Corporation said, “From this webinar, we have confirmed that there was a lot of interest regarding Genexol PM among healthcare professionals abroad. Once we obtain additional clinical data including more indications and methods of administration, Genexol PM can be used in more various ways. We will continue to host online webinars to share the latest insights on Genexol PM and other anticancer treatment with healthcare professionals in Korea and abroad.”  

  • Samyang Holdings Biopharmaceuticals Division 2021.02.05
    Samyang Biopharmaceuticals Corporation’s croquis Initiating Its Entry into the Southeast Asian Market with Participation in i-SWAM
    Samyang Biopharmaceuticals Corporation’s croquis Initiating Its Entry into the Southeast Asian Market with Participation in i-SWAM

    - Introduced the facelift thread brand croquis to healthcare professionals by participating in i-SWAM hosted in Indonesia - Director Choi Ho-sung at Piena Clinic demonstrated croquis… shared the latest facelift procedure - Promote the safety and efficacy of croquis to customers around the world through non-contact academic marketing   ▲ Samyang Biopharmaceuticals Corporation participated in International Seminar & Workshop in Aesthetic Medicine (i-SWAM) hosted in Jakarta, Indonesia from and shared the latest procedure based on its facelift thread brand croquis.   Samyang Biopharmaceuticals Corporation (CEO & President Eom Tae-ung) is promoting its facelift thread brand croquis in the Southeast Asian cosmetic surgery market.   Samyang Biopharmaceuticals Corporation announced on Jan. 28 that it participated in International Seminar & Workshop in Aesthetic Medicine (i-SWAM) hosted in Jakarta, Indonesia from Jan. 5 and shared the latest procedure based on its facelift thread brand croquis. The name croquis originates from a drawing technique that quickly sketches the outlines of a model and fittingly, the product promotes its ability to lift up the facial outlines quickly and naturally.   i-SWAM, which marks the 11th anniversary this year, is a Southeast Asian cosmetic surgery conference attended by 3,500 officials in cosmetic surgery and medicine around the world. This year, it can only be attended online until Jan. 30 due to COVID-19.   In this real-time streaming webinar, Samyang Biopharmaceuticals Corporation demonstrated a croquis-based procedure and promoted the advantages of croquis to healthcare professionals in cosmetic surgery and medicine around the world. This lecture featuring a procedure performed by Director Choi Ho-sung at Piena Clinic introduced the basic procedure with croquis to obtain the optimal effect in each part of the face, the latest procedure reflecting facelift thread trends, and other various thread lift procedures.   An official from Samyang Biopharmaceuticals Corporation said, “Indonesia is being highlighted for its high growth potential in the Southeast Asian cosmetic surgery market. Starting with Indonesia this year, we are planning to actively promote the safety and efficacy of croquis to customers around the world through non-contact academic marketing.”   Meanwhile, Samyang Biopharmaceuticals Corporation’s croquis is earning trust in the global aesthetic medicine market with data-oriented marketing, despite its disadvantages as a late comer to the market. Samyang Biopharmaceuticals Corporation aims for evidence-based marketing and is making its best effort to obtain various data to prove a correlation between operative effects in each part of the face and the thread’s physical properties, unlike traditional aesthetic thread brands that only compare and emphasize before and after effects of the operation.  

First Page 1 2 3 4 5 6 7 8 Next Page Last Page
1 2 3 4 5 6 7 8
News Search

inquiry